Madri­gal touts a mid-stage suc­cess in HeFH, cut­ting bad cho­les­terol in a com­pet­i­tive field

Madri­gal Phar­ma­ceu­ti­cals $MDGL is tout­ing a batch of pos­i­tive mid-stage da­ta from their 12-week LDL/C-low­er­ing tri­al in treat­ment-re­sis­tant pa­tients with het­erozy­gous fa­mil­ial hy­per­c­ho­les­terolemia (HeFH), an …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER